Miniature Robots Could Revolutionize Heart Infection Treatment

Engineers at Johns Hopkins University have created a pair of millimeter-scale magnetic robots designed to deliver antibiotics directly to the heart, offering a potential alternative to open-heart surgery for patients with infective endocarditis.

The innovative system, detailed in the Advanced Materials Technologies journal, consists of two cooperating robots: a barbed needle module that secures in tissue and a drug module that attaches to it. Both robots, roughly the size of a pencil tip, are controlled wirelessly by an external electromagnetic coil system, eliminating the need for batteries or motors.

The needle module acts as a semi-permanent docking station within the heart, allowing the drug module to release medication and then detach and be removed through a catheter. This design enables long-term targeted therapy without repeated invasive procedures or surgery, as the drug module can be redeployed multiple times.

Funded by the U.S. National Science Foundation, the researchers have successfully tested the robots in simulated blood flow and real pig heart tissue. The tests demonstrated the robots' ability to accurately dock, deliver medication over a three-hour period, and be safely retrieved.

According to senior paper author Axel Krieger, this development represents a significant advancement in surgical robotics.

The next steps involve testing the robots in more realistic phantom hearts that mimic the muscle contraction and beating motion of a real heart before progressing to human trials.

Infective endocarditis is a severe infection of the heart’s inner lining or valves, typically caused by bacteria or fungi entering the bloodstream. Current treatments involve weeks of high systemic doses of IV antibiotics, which often fail due to dilution by the time the medication reaches the heart. Alternative treatments include higher, potentially toxic doses of medicine or open-heart surgery, which carries significant risks and complications.

CONTEXT: This development could potentially reduce the need for high-risk open-heart surgery, offering a less invasive and more targeted approach to treating heart infections. If successful in human trials, this technology could improve patient outcomes and reduce healthcare costs associated with prolonged hospitalization and repeated invasive procedures.